(Q33811476)

29 July 2017

1 reference

title

Old, new, and emerging therapies for atopic dermatitis (English)

1 reference

29 July 2017

Sidbury R

1 reference

29 July 2017

Hanifin JM

series ordinal

1 reference

29 July 2017

publication date

1 January 2000

1 reference

29 July 2017

1 reference

29 July 2017

1 reference

29 July 2017

1 reference

29 July 2017

page(s)

1-11

1 reference

Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

The role of psoralen photochemotherapy (PUVA) in the treatment of severe atopic eczema in adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Atopic eczema unresponsive to evening primrose oil (linoleic and gamma-linolenic acids).

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Recombinant gamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Aggressive squamous cell carcinomas developing in patients receiving long-term azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Cyclosporin A in severe, therapy-resistant atopic dermatitis: report of an international workshop, April 1993

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Cyclosporine restores cytokine imbalance in childhood atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Theophylline ethylenediamine as an antipruritic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Reversible dilated cardiomyopathy following treatment of atopic eczema with Chinese herbal medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Narrow-band (TL-01) UVB air-conditioned phototherapy for chronic severe adult atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Cyclosporine in children with severe atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Staphylococcal infections in patients with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Recombinant interferon gamma therapy for atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Biochemical and immunologic mechanisms in atopic dermatitis: new targets for emerging therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Update on therapy of atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Epogam evening primrose oil treatment in atopic dermatitis and asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Evening primrose oil in atopic eczema

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Combined UVA-UVB versus UVB phototherapy for atopic dermatitis: a paired-comparison study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Intracellular interleukin-4 profiles during high-dose intravenous immunoglobulin treatment of therapy-resistant atopic dermatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Dermatological uses of high-dose intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Treatment Of Psoriasis With Oral Mycophenolic Acid

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Analysis of Chinese herbal creams prescribed for dermatological conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

High dose gammaglobulin treatment for atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Effect of topical cromoglycate solution on atopic dermatitis: combined treatment of sodium cromoglycate solution with the oral anti-allergic medication, oxatomide

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Traditional Chinese medicine for the treatment of dermatologic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Retrospective review of the use of azathioprine in severe atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

FK506 and cyclosporin, molecular probes for studying intracellular signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Treatment of eczema by EMG biofeedback and relaxation training: a multiple baseline analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases:in vivopharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Immunosuppressive effect of mycophenolic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Quality of life improvement in a patient with severe atopic dermatitis treated with photopheresis.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Topical sodium cromoglycate in the treatment of moderate-to-severe atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Anti-CD4 monoclonal antibody therapy in severe psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Oral psoralen photochemotherapy of atopic eczema

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Treatment of eczema with cyclophosphamide and azathioprine*

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Maintenance treatment with cyclosporin in atopic eczema

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Infantile eczema: A long-term follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Mycophenolate mofetil in autoimmune and inflammatory skin disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Dyshidrotic eczema treated with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Long-term application of extracorporeal photochemotherapy in severe atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Successful monotherapy of severe and intractable atopic dermatitis by photopheresis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

CD4 monoclonal antibody administration in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

THE NATURAL HISTORY OF ATOPIC DERMATITIS. A 20-YEAR FOLLOW-UP STUDY.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Tacrolimus: the drug for the turn of the millennium?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Atopic dermatitis symptoms decreased in children following massage therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

The occurrence of atopic dermatitis in north Europe: an international questionnaire study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Long-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Evening primrose oil and eczema

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

One-year follow up of children treated with Chinese medicinal herbs for atopic eczema

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Rediscovering mycophenolic acid: A review of its mechanism, side effects, and potential uses

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Long-term effectiveness and safety of recombinant human interferon gamma therapy for atopic dermatitis despite unchanged serum IgE levels.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Modulation by Chinese herbal therapy of immune mechanisms in the skin of patients with atopic eczema

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Role of interferon-gamma in immune cell regulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Renal toxicity of long-term cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

Treatment of severe atopic dermatitis in childhood with cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2805%2970141-8

7 January 2021

10.1016/S0733-8635(05)70141-8

Identifiers

DOI

1 reference

29 July 2017

1 reference